Skip to main content
. Author manuscript; available in PMC: 2014 Jul 22.
Published in final edited form as: Clin Pharmacol Ther. 2011 Jan 26;89(3):392–399. doi: 10.1038/clpt.2010.317

Figure 1.

Figure 1

Study design. Arrows denote timing of vaccinations for Schedule 1 (Week 0, 6, 12 and 26) and Schedule 2 (Week 0, 4, 8, 16, and 26). Primary endpoint (percent of subjects abstinent Week 19–26) and secondary endpoint (percent of subjects abstinent Week 19–52 are shown. NV (3’AmNic-rEPA); PBS (Phosphate buffered saline); Alum (aluminum hydroxide adjuvant); TQD (Target quit date).